UroGen Pharma Ltd. (URGN)

UroGen Pharma Ltd. (URGN) is a healthcare company (biotechnology) based in the United States. The share price is $29.27, up 4.15% on the day, which values the company at $1.44B. Price as of 17 Nov 2026, 20:44 UTC, from Yahoo Finance.

Key facts

Share price
$29.27+4.15% today
Market value
$1.44B
Forward P/E
11.7×
Funk Score
49/100
200-week average
$17.8364% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

UroGen Pharma Ltd. in more detail

URGN trades at 11.7× next year's expected earnings, 5.7× sales. It sits 64% above its 200-week average of $17.83.

Over the last five fiscal years UroGen Pharma Ltd. has compounded revenue 56.2% a year. Its Funk Score is 49 out of 100 (financial strength 2.2, profitability 2.5, growth 9.9, each out of 10).

In its favour: Five straight years of revenue growth. Worth checking: Altman Z in the distress zone; Beneish M-score flags the accounts.

2 of the superinvestors tracked here hold URGN, including Polen Capital team (0.0% of the portfolio), Cathie Wood (0.0% of the portfolio).

Superinvestors holding URGN

2 of the investors tracked here report a position in their latest 13F filing.

UroGen Pharma Ltd. (URGN): questions and answers

What is UroGen Pharma Ltd.'s market cap?

UroGen Pharma Ltd. is valued at $1.44B at a share price of $29.27.

Is URGN above its 200-week moving average?

Yes. URGN is 64.1% above its 200-week average of $17.83. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is UroGen Pharma Ltd. growing?

Over the last five fiscal years UroGen Pharma Ltd.'s revenue grew 56.2% a year.

Does URGN pay a dividend?

UroGen Pharma Ltd. does not currently pay a regular dividend.

Which famous investors own URGN?

In their latest quarterly filings, Polen Capital team (0.0% of the portfolio), Cathie Wood (0.0% of the portfolio) hold URGN. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “UroGen Pharma Ltd. (URGN) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/URGN

Underlying data: Yahoo Finance; company filings with the SEC.